Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy EyeGate Pharmaceuticals stock | $2.03

Learn how to easily invest in EyeGate Pharmaceuticals stock.

EyeGate Pharmaceuticals Inc is a biotechnology business based in the US. EyeGate Pharmaceuticals shares (EYEG) are listed on the NASDAQ and all prices are listed in US Dollars. EyeGate Pharmaceuticals employs 14 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in EyeGate Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EYEG – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

EyeGate Pharmaceuticals stock price (NASDAQ: EYEG)

Use our graph to track the performance of EYEG stocks over time.

EyeGate Pharmaceuticals shares at a glance

Information last updated 2021-10-24.
Latest market close$2.03
52-week range$1.44 - $7.85
50-day moving average $1.89
200-day moving average $3.14
Wall St. target price$11.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.63

Buy EyeGate Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Webull
Stocks, Options, ETFs
$0
0%
Get two free stocks valued between $3.00 and $300 with a deposit to any new account.
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy EyeGate Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

EyeGate Pharmaceuticals price performance over time

Historical closes compared with the close of $2.03 from 2021-10-26

1 week (2021-10-21) 2.01%
1 month (2021-09-28) 6.28%
3 months (2021-07-28) -36.76%
6 months (2021-04-28) -52.68%
1 year (2020-10-28) -43.14%
2 years (2019-10-28) -35.56%
3 years (2018-10-26) 606.82%
5 years (2016-10-28) 35.33%

EyeGate Pharmaceuticals financials

Revenue TTM $12,059
Gross profit TTM $-3,553,986
Return on assets TTM -40.35%
Return on equity TTM -103.8%
Profit margin 0%
Book value $1.47
Market capitalisation $23.5 million

TTM: trailing 12 months

Shorting EyeGate Pharmaceuticals shares

There are currently 417,950 EyeGate Pharmaceuticals shares held short by investors – that's known as EyeGate Pharmaceuticals's "short interest". This figure is 263.5% up from 114,993 last month.

There are a few different ways that this level of interest in shorting EyeGate Pharmaceuticals shares can be evaluated.

EyeGate Pharmaceuticals's "short interest ratio" (SIR)

EyeGate Pharmaceuticals's "short interest ratio" (SIR) is the quantity of EyeGate Pharmaceuticals shares currently shorted divided by the average quantity of EyeGate Pharmaceuticals shares traded daily (recently around 2.6 million). EyeGate Pharmaceuticals's SIR currently stands at 0.16. In other words for every 100,000 EyeGate Pharmaceuticals shares traded daily on the market, roughly 160 shares are currently held short.

However EyeGate Pharmaceuticals's short interest can also be evaluated against the total number of EyeGate Pharmaceuticals shares, or, against the total number of tradable EyeGate Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EyeGate Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 EyeGate Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.0457% of the tradable shares (for every 100,000 tradable EyeGate Pharmaceuticals shares, roughly 46 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against EyeGate Pharmaceuticals.

Find out more about how you can short EyeGate Pharmaceuticals stock.

EyeGate Pharmaceuticals share dividends

We're not expecting EyeGate Pharmaceuticals to pay a dividend over the next 12 months.

Have EyeGate Pharmaceuticals's shares ever split?

EyeGate Pharmaceuticals's shares were split on a 1:15 basis on 29 August 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your EyeGate Pharmaceuticals shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for EyeGate Pharmaceuticals shares which in turn could have impacted EyeGate Pharmaceuticals's share price.

EyeGate Pharmaceuticals share price volatility

Over the last 12 months, EyeGate Pharmaceuticals's shares have ranged in value from as little as $1.44 up to $7.85. A popular way to gauge a stock's volatility is its "beta".

EYEG.US volatility(beta: 0.92)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EyeGate Pharmaceuticals's is 0.9217. This would suggest that EyeGate Pharmaceuticals's shares are less volatile than average (for this exchange).

EyeGate Pharmaceuticals overview

EyeGate Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company, focuses on developing and commercializing products for treating inflammatory and immune diseases with a focus on the eye and nervous system in the United States. It develops PP-001, a clinical stage dihydroorotate dehydrogenase inhibitor that has been developed in two clinical-stage ophthalmic formulations, consisting of PaniJect that is in Phase Ia/IIb clinical trial for multiple diseases that affect the posterior region of the eye, including non-infectious posterior uveitis and diabetic macular edema; and PaniDrop, which is in Phase I safety study for multiple diseases that affect the ocular surface and anterior region of the eye, comprising of allergic conjunctivitis, viral conjunctivitis, and dry eye disease. The company also develops ocular bandage gel, a modified form of the natural polymer hyaluronic acid for corneal wound repair, and punctate epitheliopathies with a focus on dry eye. The company has license agreements with BioTime, Inc. Eyegate Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Waltham, Massachusetts.

Frequently asked questions

What percentage of EyeGate Pharmaceuticals is owned by insiders or institutions?
Currently 12.049% of EyeGate Pharmaceuticals shares are held by insiders and 24.634% by institutions.
How many people work for EyeGate Pharmaceuticals?
Latest data suggests 14 work at EyeGate Pharmaceuticals.
When does the fiscal year end for EyeGate Pharmaceuticals?
EyeGate Pharmaceuticals's fiscal year ends in December.
Where is EyeGate Pharmaceuticals based?
EyeGate Pharmaceuticals's address is: 271 Waverley Oaks Road, Waltham, MA, United States, 02452
What is EyeGate Pharmaceuticals's ISIN number?
EyeGate Pharmaceuticals's international securities identification number is: US30233M5031
What is EyeGate Pharmaceuticals's CUSIP number?
EyeGate Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 30233M107

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site